Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: Clinical and economic consequences

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2757-2764

  Sicras Mainar, Antoni ^a   Navarro Artieda, Ruth ^b   Blanca Tamayo, Milagrosa ^a   Gimeno De La Fuente, Victoria ^c   Salvatella Pasant, Jordi ^c  

^a Badalona Serveis Assistencials   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c H LUNDBECK A S   (Denmark)

Author keywords

Antidepressants; Health care costs; Major depressive disorder; Non health care costs; Outpatient care; Remission; Resource usage

Indexed keywords

CITALOPRAM; ESCITALOPRAM; VENLAFAXINE;

ADULT; AGED; ARTICLE; COMORBIDITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSERVATIONAL STUDY; REMISSION; RETROSPECTIVE STUDY; SPAIN;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78349235764     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.529430     Document Type: Article

References (34)

1. Thomas MR, Waxmonsky JA, Gabow PA, et al. Prevalence of psychiatric disorders and costs of care among adult enrollees in a medicaid HMO. Psychiatr Serv 2005;56:1394-401
2. Haro JM, Palac?́n C, Vilagut G, et al. Grupo ESEMeD-España. Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain. study Med Clin (Barc) 2006;126:445-51
3. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ 2006;9:87-98
4. Crisp R. Depression and occupational disability in five diagnostic groups: a review of recent research. Disabil Rehabil 2007;29:267-79
5. Sobocki P, Lekander I, Borgstrom F, et al. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 2007;22:146-52
6. Shvartzman P, Weiner Z, Vardy D, et al. Health services utilization by depressive patients identified by the MINI questionnaire in a primary care setting. Scand J Prim Health Care 2005;23:18-25
7. Sicras Mainar A, Navarro Artieda R, Rejas Gutié rrez J, et al. Comorbilidad y coste ambulatorio asociado a los pacientes con trastornos depresivos en un á mbito poblacional. Farm Hosp 2007;31:101-5
8. Keller MB. Past, present and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003; 289:3152-60
9. Zimmernan M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 2006;163:148-50
10. National Institute for Clinical Excellence. Depression: Management of Depression in Primary and Secondary Care. Clinical Guideline 23. London: NICE, 2004. Amended, 2006
11. American Psychiatric Association Practice Guidelines. Treatment of Patients with Major Depressive Disorder, 2nd Edn. April 2000
12. Fernández A, Haro JM, Mart?́nez-Aloso M, et al. Treatment adequacy for anxiety and depressive disorders in six European countries. Br J Psychiatry, 2007 : 190: 172-3.
13. Anon. El Mercado Farmacéutico. IMS Health, April 2009
14. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734-50
15. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antide-pressive agents for depression. Cochrane Database Syst Rev 2009;2: CD006532
16. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;259:172-85
17. Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008;24:2587-95
18. Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008;14:426-41
19. Chenu F, Batten LA, Zernig G, et al. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry 2009;70:958-66
20. Anon. Guidelines for ATC Classification. Oslo: Nordic Collaborating Centre for Drug Statistics Methodology, 1991
21. Lamberts H, Wood M, Hofmans-Okkes IM (eds). The International Classification of Primary Care in the European Community. With a Multi-Language Layer. Oxford: Oxford University Press, 1993
22. Conde V, Franch JL. Escalas de evaluación comportamental para la cuanti-ficación de la sintomatolog?́a psicopatoló gica en los trastornos angustiosos y depresivos. Editorial: Departamento de psicolog?́a médica y de psiquiatr?́a del Hospital Cl?́nico de la Facultad de Medicina de Valladolid, 1984
23. Sicras-Mainar A, Blanca-Tamayo M, Gutié rrez-Nicuesa L, et al. Clinical validity of a population database definition of remission in patients with major depression. BMC Public Health 2010;10:64
24. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
25. Weiner JP, Starfield BH, Steinwachs DM, et al. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991;29:452-72
26. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200
27. Sackett D, Rosenberg W, Gray J, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2
28. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
29. Sicras-Mainar A, Blanca-Tamayo M, Gutié rrez-Nicuesa L, et al. Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisión de la depresión mayor en España: estudio longitudinal de ámbito poblacional. Gac Sanit 2010;24:13-19
30. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009;166:599-607
31. Wade AG, Saragoussi D, Despié gel N, et al. Healthcare expenditure in severely depressed patients treated with escitalopram generic SSRIs or venlafaxine in the UK. Curr Med Res Opin 2010;26: 1161-70
32. Fantino B, Moore N, Verdoux H, et al. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007;22: 107-15
33. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
34. Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepres-sant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73